James Investment Research Inc. Has $1.66 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

James Investment Research Inc. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 37.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,075 shares of the biopharmaceutical company’s stock after purchasing an additional 7,903 shares during the period. James Investment Research Inc.’s holdings in Halozyme Therapeutics were worth $1,664,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in HALO. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after buying an additional 1,988,238 shares during the period. Handelsbanken Fonder AB increased its stake in Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Halozyme Therapeutics by 28.1% during the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after purchasing an additional 557,350 shares during the period. Boston Trust Walden Corp bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $23,211,000. Finally, Swedbank AB acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at about $13,927,000. 97.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HALO has been the topic of several recent research reports. The Goldman Sachs Group increased their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday. Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $57.15 on Friday. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The company has a market capitalization of $7.24 billion, a PE ratio of 22.15, a PEG ratio of 0.49 and a beta of 1.27. The stock’s 50 day moving average price is $56.99 and its 200-day moving average price is $51.94. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total value of $557,200.00. Following the transaction, the director now directly owns 89,755 shares in the company, valued at $5,001,148.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Matthew L. Posard sold 10,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total transaction of $557,200.00. Following the sale, the director now directly owns 89,755 shares in the company, valued at approximately $5,001,148.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 89,881 shares of company stock worth $5,169,834. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.